View the NDEWS Weekly Briefing Issue 307 ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­
webversion | unsubscribe | update profile
 
Issue 307: October 16, 2026
 
new briefing header (1)
 

This Week's Focus: Ketamine

 
 

This week’s NDEWS Weekly Briefing focuses on ketamine, a substance that has received increasing attention across public health, clinical, law enforcement, and research settings. While ketamine continues to be studied and used in the treatment of certain psychiatric conditions, recent reports have documented increasing non-medical use, expanding illicit markets, and growing concerns related to diversion, misuse, overdose, and adverse health consequences. Recent international law enforcement reporting has also highlighted ketamine's growing presence in the global synthetic drug market.

Featured this week are an NDEWS Special Report on ketamine-related overdose trends, our most recent NDEWS Web Monitoring Report on ketamine and a collection of recent publications examining ketamine use in psychiatric treatment, self-treatment of mental health conditions, recreational settings, and emerging public health concerns. Together, these resources provide a snapshot of the evolving role of ketamine in both medical and non-medical contexts and underscore the importance of continued monitoring of ketamine-related trends across diverse populations and settings.

As always, we welcome your input.
 
context_submission_call_to_action_box-_subscribe
 

NDEWS ORIGINAL CONTENT

 
 

NDEWS Special Report: National Trends in EMS Encounters for Suspected Nonfatal Overdoses Involving Ketamine by Age Group January 1, 2023 - September 30, 2026

 
ketamine_age-recovered_page_1
ketamine_age-Recovered_Page_2-scaled
ketamine_age-recovered_page_3
 

Click here for a PDF version of the report.
Click here to learn more about the NDEWS Special Reports.
 
share your thoughts-01
twitter button-01

 

NDEWS Web Monitoring Report: Ketamine

 
8-16-26_ndews_2026_sum-of-ketamine-reddit-posts-and-unique-users-in-a-rolling-14-day-window-1
 

What is Ketamine? Ketamine is a dissociative anesthetic used in human and veterinary medicine. Nonmedical use most often involves snorting powder typically called “bumps” or “lines,” and higher doses can produce an intense dissociative state known as a “k-hole”; common slang terms include “K,” “ket,” and “special K.”

Why are we reporting on this?
Ketamine has received elevated media attention and public interest regarding substance use trends within higher education, accompanied by sustained online discussions concerning its consumption among college-aged populations and young adults. On Reddit, ketamine use in collegiate settings is frequently discussed as part of broader polysubstance patterns at parties, gatherings with friends, and events involving fraternity and sorority crowds. Commenters detail hazardous practices such as frequent or daily consumption, co-ingestion with alcohol, prescription stimulants, cocaine, psychedelics, opioids, and benzodiazepines, as well as adverse outcomes including acute panic, extreme dissociation, paranoia, disruptions to academic responsibilities, and seek or require medical care to treat symptoms. In addition, these discussions highlight ongoing concerns regarding family reactions and institutional responses from universities following substance-related incidents.

Public Health Impacts:
Discussants describe frequent or daily ketamine use, relapse, and difficulty stopping, often alongside dependence on other substances such as benzodiazepines. Commenters report extreme dissociation, paranoia, and feeling overwhelmed after use, and a few describe bladder problems linked to frequent ketamine or other dissociative use. A few commenters who are college or university students and describe using ketamine also describe hospital or emergency care after polysubstance use or overdose. In addition, commenters frequently report functional setbacks, including neglected coursework, missed examinations, academic suspension, and challenges managing comorbid psychological conditions like attention-deficit/hyperactivity disorder (ADHD), depression, and polysubstance dependence.

How is it Being Discussed? Reddit commenters describe ketamine use in a range of contexts, including recreational nightlife, attempts to manage pain or mental health symptoms, coping with academic stress, and offsetting the effects of cocaine, LSD, or prescription stimulants. Discussions frequently describe ketamine as part of polysubstance use rather than as a standalone substance, with mentions of combinations involving psychedelics, stimulants, cannabis, alcohol, benzodiazepines, opioids, pregabalin, and other substances. Posts describe use at parties, fraternity and sorority events, and gatherings with friends, most commonly through intranasal administration, including “bumps” or “lines,” with some reports of intramuscular or intravenous injection. Commenters also discuss dissociative experiences, including “k-holes,” describing a range of subjective effects such as relaxation, introspection, disorientation, panic, and detachment from their surroundings. Some individuals with ADHD describe using ketamine alongside prescribed stimulants, including in the context of studying, while others discuss maintaining academic responsibilities despite frequent substance use or expressing difficulty controlling their consumption. Discussions also address the perceived prevalence of drug use in college social circles, its compatibility with academic demands, and concerns about how universities and families respond to substance-related incidents, including campus security involvement, university-arranged hospital care, and concealing substance use from parents. Public health discussions include concerns about dosing, reagent testing for potential adulterants, and the effects of habitual use.

Drug Terms: Ketamine, Ket, Special K, and K-hole, each combined with college, university, undergrad, undergraduate, campus, dorm, fraternity, frat, sorority, student, higher education, freshman, and sophomore.

Click here to learn more about the NDEWS Online Monitoring.
 
share your thoughts-01
twitter button-01

 

RECENT PUBLICATIONS & REPORTS

 
 

'Special K' didn’t retire when Spravato arrived

 
7-11-25_psychology_today
 

This week's article in Psychology Today by NDEWS SAG Member Mark Gold examined ketamine’s continued use and misuse in the context of its growing role in psychiatric treatment. The article describes ketamine’s dissociative effects, its history as a recreational drug known as “Special K,” and concerns related to incapacitation, addiction, diversion, and drug-facilitated sexual assault. The article notes that ketamine use among New York City nightclub attendees increased between 2017 and 2024 and discusses reports of ketamine-associated harms, including severe urinary tract injury, cognitive and psychiatric effects, and overdose deaths. Gold emphasizes that while esketamine (Spravato) is administered in certified medical settings with monitoring requirements, ketamine prescribed for depression remains an off-label treatment that requires careful patient screening, supervision, and follow-up.

Read the full article here.
 
share your thoughts-01
twitter button-01

 

Expanding ketamine and vape-based drug market exposed in international police operation

 
interpol-logo
 

A recent report from International Criminal Police Organization (INTERPOL) highlighted increasing non-medical ketamine use and expanding ketamine trafficking identified during Operation Lionfish-Mayag IV. The international law enforcement operation, which involved 17 countries, resulted in the seizure of 17 tons of ketamine, marking the first time in an INTERPOL operation targeting synthetic drugs that ketamine surpassed methamphetamine in seizure volume. According to the report, the increase reflects a global pattern of increasing non-medical ketamine use, driven in part by lower prices and easier manufacturing compared with other drugs. The report also described evidence of large-scale ketamine manufacturing and trafficking in Southeast Asia and European-sourced postal supply chains supplying markets in Australia and the United States.

Read the full report here.
 
share your thoughts-01
twitter button-01

 

Differentiating intentional ketamine use from unintentional exposure as an adulterant using oral fluid testing

 
10-15-26_journal-of-forensic-sciences
 

A recently published study in the Journal of Forensic Sciences led by NDEWS Co-Director Joseph Palamar and co-authored by NDEWS SAG Member Alex Krotulski compared oral fluid ketamine test results with self-reported recent use to assess whether detected ketamine reflected intentional use or possible unintentional exposure from adulterated drugs. The results of the study determined that among those testing positive for ketamine, only 41.5% reported past 24-hour use. The authors concluded that norketamine detection was the strongest predictor of self-reported use, but relying solely on norketamine detection or higher ketamine concentration cutoffs may miss some cases of use or exposure.

Read the full study here.
 
share your thoughts-01
twitter button-01

 

Trends in nonmedical ketamine use, poisonings, related deaths, pharmaceutical diversions, and law enforcement seizures: results from annual population-based repeated cross-sectional studies

 
4-11-25_the_lancet_regional_health_americas
 

A published observational study in The Lancet Regional Health – Americas led by NDEWS Co-Director Joseph Palamar examined illicit ketamine from eight unique annual repeated cross-sectional studies. The results indicated that nonmedical ketamine use in the US is rising among adults, while adolescent use continues to decline. Poisonings and pharmaceutical diversions have risen along with law enforcement seizures, which indicates a growling illicit availability.

Read the full article here.
 
share your thoughts-01
twitter button-01

 

Trends in ketamine use among nightclub attendees in New York City, 2017–2024

 
5-9-25_international_journal_of_drug_policy
 

A study in the International Journal of Drug Policy by NDEWS Co-Director Joseph Palamar, analyzed survey data from 3,332 New York City nightclub attendees between 2017 and 2024. Past-month ketamine use rose from 3.1% to 6.8% (a 118% increase), with the steepest increases among adults aged 26 and older, females, college graduates, and sexual minorities. Ketamine use was strongly associated with past-month cocaine (aOR=8.17), LSD (aOR=8.46), and MDMA (aOR=2.76) use.

Read the study here.
 
share your thoughts-01
twitter button-01

context_submission_call_to_action_box-_subscribe
 

UPCOMING WEBINARS & EVENTS

 
nascsa-conference-horizontal-ad
 

National Association of State Controlled Substances Authorities 42nd Annual Conference

 
 

NASCSA’s 2026 Annual Conference is the best place to stay informed, connect with colleagues, and learn about the ever-changing landscape of state and federal regulations. This conference brings together state and federal government officials and industry experts, making it an essential networking and learning opportunity. Attendees can exchange ideas and gain invaluable knowledge and insight from peers and experts alike.

Where:
Holiday Inn By the Bay – Portland, Maine

When:
October 26-29, 2026

Click here to register.
 
share your thoughts-01
twitter button-01

2027_toronto_cpdd-2

Horizontal NDEWS banner with a dark blue background. On the left, the NDEWS logo reads “NDEWS: National Drug Early Warning System.” On the right, an orange button states “Submit feedback anytime to our Reader Response form,” with a white hand cursor icon indicating a clickable link.
 

NDEWS OPPORTUNITIES

 
 

Join the UF T32 Training Program in Substance Abuse and Public Health as a Pre or Postdoc! Work with the NDEWS Team!

 
2025-nida-t32-postcard
 

Are you committed to advancing the science of substance use and public health? The University of Florida’s NIDA-funded T32 Training Program offers predoctoral and postdoctoral scholars an exceptional opportunity to launch impactful research careers focused on NDEWS!

What We Offer:
- Interdisciplinary training at the intersection of addiction science, epidemiology, and surveillance
- Mentorship from leading UF faculty in epidemiology, public health, psychology, medicine, and more
- Hands-on research with landmark and important NIH-funded projects and access to rich data
- Career development support, including grant writing, publishing, and professional networking
- A collaborative, inclusive research community committed to reducing the burden of substance use

Eligibility:
- US citizens or permanent residents
- Interested in a PhD in Epidemiology, or early-stage postdoctoral fellows
- Demonstrated interest in substance use, addiction, or public health research

Location: Gainesville, Florida — a dynamic hub for scientific innovation with high quality of life and low cost of living.
 
 
Click Here To Apply
 

 

ABOUT NDEWS

 
 

The NDEWS Weekly Briefing curates emerging data and findings from across the Early Warning Network, which includes three core components: our Scientific Advisory Group (SAG), comprised of national experts and federal partners; our Sentinel Site Directors (SSDs), who lead local surveillance in key geographic regions; and our Community-Based Health Experts, who provide on-the-ground insights from populations most impacted by drug trends. Together, these contributors generate timely, multidisciplinary and impactful information, ranging from peer-reviewed research findings to local surveillance data. These contributions inform public health and research communities.
 
NDEWS Submission Form Graphic (6)
 

Get in Touch with NDEWS

Share your research, news, and events through our submission form.
Share information on drug trends in your community through our get involved form.
Share your comments on our newsletter through our
feedback form.
For more information on NDEWS' efforts, visit our website.
Follow NDEWS on Twitter/X: @NDEWSnews
If you miss or want to learn more about NDEWS Original Content, you can find our archived content on the NDEWS website:
     • NDEWS Special Reports using substance-related EMS data
     • NDEWS Rapid Street Reporting (RSR) survey data reports
     • NDEWS Web Monitoring Team Reddit Alerts
     • NDEWS Sentinel Site Reports
     • Previous issues of the NDEWS Weekly Briefings
 
email_footer-2-2
 

The Weekly Briefing is a newsletter published each week by the National Drug Early Warning System (NDEWS) Coordinating Center, which is funded by the National Institute on Drug Abuse (U01DA051126) to the University of Florida (MPI: Cottler (contact), Co-Is: Goldberger, Nixon, Striley), NYU Langone Health (MPI: Palamar), and Florida Atlantic University (Co-I: Barenholtz). 
NDEWS briefings, reports, and figures may be shared, reproduced, or excerpted, provided NDEWS is appropriately attributed, and a link to the original source material is included. NDEWS materials must not be sensationalized with language or imagery. Reference must be made to the most current version of the original NDEWS source material so as not to disseminate outdated or inaccurate information. NDEWS does not endorse or assume responsibility for third-party interpretation, commentary, or AI-generated content, including images, which use or reference NDEWS materials.